Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ABX-1431 in Central Pain
NCT03138421Phase 1Completed
- Sponsor
- Abide Therapeutics
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in central neuropathic pain (CNP) comparing ABX-1431 HCl with Placebo (2 arms). Primary endpoint: Change in mean pain score based on the Pain NRS-11 ordinal numeric rating scale at 14 days. Started Aug 2017; status: completed.
02
Drugs
ABX-1431
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on NCT03138421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138421.